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Mutation in Pyrroline-5-Carboxylate Reductase 1 Gene
in Families with Cutis Laxa Type 2
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Autosomal-recessive cutis laxa type 2 (ARCL2) is a multisystem disorder characterized by the appearance of premature aging, wrinkled
and lax skin, joint laxity, and a general developmental delay. Cutis laxa includes a family of clinically overlapping conditions with
confusing nomenclature, generally requiring molecular analyses for deﬁnitive diagnosis. Six genes are currently known to mutate to
yield one of these related conditions. We ascertained a cohort of typical ARCL2 patients from a subpopulation isolate within eastern
Canada. Homozygosity mapping with high-density SNP genotyping excluded all six known genes, and instead identiﬁed a single homo-
zygous region near the telomere of chromosome 17, shared identically by state by all genotyped affected individuals from the families. A
putative pathogenic variant was identiﬁed by direct DNA sequencing of genes within the region. The single nucleotide change leads to
amissensemutation adjacent to a splice junction in the gene encoding pyrroline-5-carboxylate reductase 1 (PYCR1). Bioinformatic anal-
ysis predicted a pathogenic effect of the variant on splice donor site function. Skipping of the associated exon was conﬁrmed in RNA
from blood lymphocytes of affected homozygotes and heterozygous mutation carriers. Exon skipping leads to deletion of the reductase
functional domain-coding region and an obligatory downstream frameshift. PYCR1 plays a critical role in proline biosynthesis. Patho-
genicity of the genetic variant in PYCR1 is likely, given that a similar clinical phenotype has been documented for mutation carriers of
another proline biosynthetic enzyme, pyrroline-5-carboxylate synthase. Our results support a signiﬁcant role for proline in normal
development.Cutis laxa type 2 (ARCL2, [MIM 219200]) is an autosomal-
recessive multisystem disorder with prominent connec-
tive-tissue features characterized by the appearance of
premature aging, particularly wrinkled and lax skin with
reduced elasticity. It falls in a family of related disorders
including cutis laxa type 1 (MIM 219100), gerodermia
osteodysplastica or Walt Disney dwarﬁsm (MIM 231070),
andwrinkly skin syndrome (MIM278250) and is sometimes
referred to as cutis laxa with growth and developmental
delay, or as cutis laxawith joint laxity and retarded develop-
ment. Deﬁnitive criteria for distinguishing all of these
conditionsunambiguously is lacking, involvinga subjective
element to clinical diagnosis. Thus, molecular diagnosis is
proving increasingly useful in resolving these phenotypi-
cally similar disorders. Mutations have been identiﬁed in
ﬁve genes in patients and families segregating these related
clinical presentations, speciﬁcally Egf-containing ﬁbulin-
like extracellular matrix protein 2 (EFEMP2, alias ﬁbulin 4
[MIM 604633]),1,2 ﬁbulin 5 (FBLN5 [MIM 604580]),3–6
ATPase, Hþ transporting, V0 subunit a2 (ATP6V0A2 [MIM
611716]),7 elastin (ELN [MIM 130160]),8–11 and SCYL1
binding protein (SCYL1BP1 [MIM 607983]).12 Mutations
have also been found in a sixth gene, aldehyde dehydroge-
nase 18 family, member A1 (ALDH18A1, alias pyrroline
5-carboxylate synthase [PYCS] [MIM 138250]), in patients
described with a so-called neurocutaneous syndrome
closely resembling cutis laxa type 2.13–15 These six genes120 The American Journal of Human Genetics 85, 120–129, July 10,represent a variety of biochemical processes. The pheno-
typesalsovary amongthedescribedpatients, bothclinically
and biochemically, as to whether there is involvement of
proteinN- orO-glycosylation, found to be defective in asso-
cation with the ATP6V0A2 mutations, although this gene
may not explain the symptoms of all such patients.7,16–18
Notably, there are numerous literature reports of cases
resembling this suite of phenotypes, either unexplained or
untested for the known genes.19–24
In the course of regular clinical practice, we ascertained
two Maritime Canadian pedigrees of French Acadian
descent, one with four individuals diagnosed with
ARCL2 and one with one such individual (Figures 1A and
1B). All of the patients displayed lax, wrinkled skin with
reduced elasticity, lax joints, andmild craniofacial dysmor-
phic features (Figure 2). The loose skin was most promi-
nent over the dorsum of the hands and feet. Craniofacial
dysmorphism included microcephaly, broad and promi-
nent forehead, prominent ears, blue sclerae, and sagging
cheeks. The patients looked substantially older than their
chronologic ages. Joint laxity was most prominent in the
small joints of the hands and feet, and two patients had
congenital hip dislocation. All patients had intrauterine
growth retardation and at least some degree of postnatal
growth deﬁciency. All ﬁve showed developmental delay.
Two affected individuals had demonstrated agenesis of
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Figure 1. Maritime Families Segregating Cutis Laxa Type 2
Affected individuals VI:4 in the large family 1 and V:1 in the small family 2 (arrowheads) are the probands. Numbers below selected indi-
viduals are DNA and/or RNA sample numbers, as noted in text and ﬁgures. Clinically affected patients are indicated with ﬁlled black
symbols.have enlarged ventricles. There was no obvious metabolic
pathology ascertained by routine blood and urine metabo-
lite analysis. There was no corneal clouding or athetosis, as
might be expected for de Barsy syndrome. There was no
clinical evidence requiring X-ray or bone mineral density
scan; hence, these procedures were not performed. Protein
glycosylation and wound healing were normal. See Table 1
for detailed clinical ﬁndings. Approval for a research study
was obtained from the IsaakWalton Killam (IWK) Hospital
Research Ethics Board. All sampled family members or
parents provided written informed consent to participate
in the study. DNA was obtained from living patients’ and
relatives’ blood samples via routine extraction methods.
All procedures were in accordance with ethical and meth-
odological standards for human experimentation.
Together, the clinical ﬁndings most resemble ARCL2 as
described in the literature. In addition to sharing ethnic
heritage, the two families reside near each other, consistent
with the possibility of a founder effect. To test this, we gen-
otyped a total of 13 DNA samples, including four of the
ﬁve affected patients (sampled from both families) and
nine unaffected relatives from the two pedigrees, using
a high-density SNP genotyping array containing approxi-
mately 330,000 biallelic markers. Whole-genome SNP
scanning was performed at McGill University and the
Genome Quebec Centre for Innovation with the use of
the Illumina HumanHap300v2_A panel. Homozygosity
was assessed by computational inspection for long runsThe Amof consecutive homozygous SNPs identical by state in the
four Maritime Canadian affected patients, followed by
visual inspection of the longest runs for informativeness
in unaffected family members.This analysis deﬁned one
chromosomal region of approximately 1.4 Mbp, near the
tip of chromosome 17 (17q25.3), where all four genotyped
affected patients from both families shared 134 consecu-
tive SNPs homozygous with the same genotypic status
(Figure 3, Table 2, Figure S1). The next largest region of
sharing comprised only 40 consecutive SNPs and fell
within the general distribution of miscellaneous short
homozygous segments. Formal linkage analysis supported
the chromosome 17 locus, although the two-point LOD
scores were less than 2 for all hits in the genome (data
not shown) as a result of the poorly informative pedigree
structure. The region thus deﬁned on chromosome 17
includes all or part of 50 RefSeq annotated genes.
For mutation detection, annotated coding exons were
ampliﬁed from genomic patient DNA by PCR via standard
methods and sequenced at McGill University and the
Genome Quebec Centre for Innovation, or at Dalhousie
University with Sanger ﬂuorescent sequencing and capil-
lary electrophoresis (Table S1). Sequence traces were
analyzed with MutationSurveyor (Soft Genetics). One
obvious gene candidate, nuclear prelamin A recognition
factor (NARF), was screened ﬁrst because of the association
of laminAwithother progeroid genetic disorders.However,
NARF did not contain any obvious causal mutations. Inerican Journal of Human Genetics 85, 120–129, July 10, 2009 121
total, we sequenced most or all of the coding regions of 11
genes in the interval (NARF [MIM 705349], HGS [MIM
604375], HEXDC, PYCR1 [MIM 179035], RAB40B, ARHG-
DIA [MIM 601925], DUS1L, MRPL12 [MIM 602375],
Figure 2. Clinical Presentations of Patients with Cutis Laxa
Type 2
Shown are (A) hands (11156), (B) face (D05-09864), and (C) feet
(11156) of case individuals aged 12, 11, and 12 years, respectively,
at the time of photography. Note the appearance of premature
aging, particularly wrinkled skin and joint laxity.122 The American Journal of Human Genetics 85, 120–129, July 10,NPLOC4, RAC3 [MIM 602050], and TBCD [MIM 604649]),
until a potentially pathogenic variant, c.797G>A
(p.Arg266Gln), was found in the gene encoding pyrroline-
5-carboxylate reductase 1 (PYCR1). This was a single-nucle-
otide change, altering the last amino acid encoded by exon
6 of the gene, R266, and also potentially altering the splice
donor site (Figure 4A). The mutation segregated in the
family as expected on the basis of SNP genotyping: all
four affected individuals were homozygous, all obligatory
carriers were heterozygous, and some unaffected siblings
were heterozygous for the mutation (data not shown) The
mutation was not in dbSNP and was not found among 96
CEPH control DNAs. Among 142 Maritime population
control samples, one sample was heterozygous for the
mutation; there were no homozygotes. Our local control
samples are known to include individuals of Acadian
ethnicity, as in our ARCL2 patient families; therefore, it is
not unlikely that a heterozygote for a recessively acting
causal mutation might be observed among these controls.
Our results are consistentwith a founder effect of thismuta-
tion in the Acadian population; no other identiﬁed cases of
ARCL2 from the region could be identiﬁed through inten-
sive outreach among regional clinicians.
The potential pathogenic effect of the mutation was ﬁrst
studied bioinformatically. Residue R266 is completely
conserved across vertebrate evolution (Figure S2). The
missense mutation R266Q was predicted to have a delete-
rious effect on protein function by SIFT, PANTHER, and
Align-GVGD, but was predicted as benign by PolyPhen
(Table S2). The results suggest that the missense mutation
R266Qmight affect protein function. The potential impact
of the mutation on splicing was also analyzed with Net-
Gene2, SplicePort, and SplicePredictor. Genomic sequence
NC_000017.9 was used as the input wild-type DNA
sequence, and the DNA sequence with one base change,
g.2767G>A, was used as the input mutant sequence.
The exon 6 splice donor site was correctly predicted in the
wild-type sequence by all three programs. The three
methods also correctly identiﬁed other donor sites of the
reference sequence. In the mutant sequence, however, the
exon 6 donor site could no longer be identiﬁed by any of
the three programs. This suggested that themutationmight
also interfere with correct splicing of the primary PCYR1
transcript. We tested this directly by examining RNA ex-
tracted from patients’ blood lymphocytes.
We were able to amplify spliced products of PYCR1 by
nested RT-PCR from total RNA of blood lymphocytes
(although not from salivary RNA). For sequencing of cDNA
generated from lymphocyte RNA, buffy coats were prepared
from fresh blood draws and approximately 5 3 105cells
were extracted with the use of the QIAGEN RNeasy kit,
in accordance with standard protocol for cells. Two micro-
liters of total RNA was used as template for two rounds of
nested RT-PCR with the Invitrogen M-MLV kit, including
the use of Invitrogen RNaseOUT. An unrelated control
sample generated the expected size product for mRNA,
correctly splicing exons 5, 6, and 7 (Figures 4B and 4C).2009
Table 1. CL2 Clinical Details in Maritime Patients and the Literature
Clinical Feature CL Type 2 WSS GO NC 11807 D05-09864 11556 12827 No DNA
General
IUGR þ þ þ þ þ þ þ
Failure to thrive þ þ þ þ þ þ ?
Developmental delay þ þ þ þ þ þ þ þ þ
Feeding problems reﬂux þ reﬂux - þ
DYSMORPHISM
Microcephaly þ þ þ þ þ þ þ ? þ
Broad, prominent forehead þ þ þ þ þ þ
Long philtrum þ - þ - -
Midface hypoplasia þ malar þ - þ
Epicanthal folds þ þ - - -
Downslanting palpebral ﬁssures þ - þ
Large, bulbous nose þ þ -
Prognathism þ - þ/ -
Retrognathia - - -
Large, protruding ears þ þ þ þ
Hypertelorism þ þ/ þ þ -
Blue sclera þ/? - þ - þ þ þ
Sagging jowls þ - þ þ þ þ þ þ
Large fontanelle þ þ/NM - - þ þ þ
Pinched nose þ þ þ þ
High palate þ - -
Triangular face þ þ - þ þ
Deep set eyes - þ þ
Musculoskeletal
Lax joints þ þ þ þ þ þ þ þ þ
Hip dislocation þ þ þ þ þ - ? - þ
Winged scapulae NM þ - - - - -
Spinal deformity þ - - -
Fractures - - -
Pectus excavatum - - þ þ - -
Diminshed muscle mass þ þ þ - -
Hypotonia þ þ þ þ - - -
Scoliosis þ þ -
Long digits þ þ -
Clasped thumb þ þ þ
Cutaneous
Wrinkly skin þ þ þ þ þ þ
Prominent veins/translucent skin þ þ þ þ þ þ þ þ þ
Prominent palmar/plantar creases þ þ - þ
Lax skin with reduced elasticity þ þ þ þ þ þ þ
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Table 1. Continued
Clinical Feature CL Type 2 WSS GO NC 11807 D05-09864 11556 12827 No DNA
Radiology
Osteoporosis þ -
Vertebral anomalies þ -
Wormian bones þ - þ
Other
Inguinal hernia þ -/NM þ 1 of 4 - - þ
Umbilical hernia þ -/NM þ þ (?) - -
Congenital heart disease -/NM - - - þ
Pulmonary emphysema - - - -
Renal defect - -/NM - - -
Hydrocephalus - þ - þ
Jaundice þ - - þ
CNS involvement þ þ - þ
Agenesis of the corpus callosum þ þ -
Respiratory tract infection ? þ - ?
Easy bruising þ ? þ
Aortic root aneurysm - - -
Clinical features of Acadian ARCL2 patients (last 5 columns) versus literature review of other descriptions of cutis laxa type 2 with developmental delay, wrinkly skin
syndrome (WSS), gerodermia osteodysplastica (GO), and neurocutaneous syndrome (NC).13–15,21,22,44–46However, in two homozygous mutation-bearing individ-
uals from our pedigree, a smaller size band was uniquely
detected, which upon sequencing represented an aberrant
splice product of exon 5 to exon 7, skipping exon 6
(Figures 4B and 4D, Figure S3). Heterozygous mutation
carriers contained a mixture of RNA with normal
and skipped products (Figures 4B and 4C). Skipping of
exon 6 deletes 54 amino acids of the PYCR1 protein,
including the conserved reductase functional signature124 The American Journal of Human Genetics 85, 120–129, July 10,(Figure 5), and also generates an obligatory frameshift in
the downstream exon(s), leading to premature termina-
tion of the open reading frame, and is reasonably
presumed to be pathogenic. The nested RT-PCR protocol
is qualitative, although signal strengths were comparable
for the correctly spliced and skipped RNA-derived bands
in the control and homozygous affected lymphocyte
samples treated similarly. In the heterozygous carriers,
the skipped RNA signal was weaker than that of theFigure 3. Homozygosity Mapping
Four ARCL2 mutation-affected individuals
(family 1: IV:7, VI:1, VI:4; family 2: V:1)
were genotyped as described in the text.
They share a region of homozygosity close
to the telomere of chromosome 17q
(far right in ﬁgure). SNP genotypes (coded
as AA, AB, or BB) for all of chromosome
17 are represented by vertical lines with
different colors. AA: light blue, BB: light
green, AB: red. Unaffected ﬁrst-degree
relatives were heterozygous for many
SNPs within the shared homozygous
region of the affected individuals at
17q25.3 (Figure S1).2009
Table 2. Homozygosity Analysis of CL2
nSNPs Chr BeginSNP EndSNP Begin End Size
134 17 rs9894429 rs6502043 77,207,216 78,634,366 1,427,151
40 1 rs4652869 rs12074848 35,151,521 36,357,664 1,206,144
33 20 rs6088813 rs7263536 33,438,595 34,110,871 672,277
29 2 rs1455653 rs11692344 198,186,565 198,504,108 317,544
29 4 rs6531772 rs6849339 33,432,805 34,032,949 600,145
28 7 rs4646450 rs6967487 99,104,254 99,440,127 335,874
28 10 rs2247247 rs715687 84,373,257 84,561,933 188,677
28 14 rs11626364 rs2109750 73,319,563 73,741,009 421,447
28 18 rs17240415 rs1431419 64,801,868 64,889,909 88,042
25 5 rs4267850 rs9293757 77,683,520 77,959,776 276,257
The ten longest runs of homozygous SNPs shared identically by state (IBS) in the four genotyped affected CL2 patients are shown in decreasing order of number of
consistent contiguous SNPs. Headings indicate number of SNPs, chromosome, starting and ending SNPs (meaning first inconsistent heterozygous or non-IBS SNP
at each end of each interval, yielding maximal interval extent), and beginning and ending nucleotides of each interval, according to human genome assembly
hg36, based on first and last inconsistent SNPs. Interval size is given in megabase pairs (Mbp).correctly spliced band in the same samples and gel lanes,
suggesting some amount of nonsense-mediated decay or
other destabilization of the incorrectly spliced product.
However, the skipped product was readily detectable in
both homozygous affected individuals and heterozygous
carriers, so such an effect, if present, appears unrelated to
the clinical penetrance of the mutation.
Our results strongly suggest that loss of PYCR1 gene
activity is responsible for the clinical ARCL2 phenotype in
our patients. It is particularly noteworthy that this is the
second enzyme of proline metabolism implicated in cutis
laxa, the ﬁrst being pyrroline-5 carboxylate synthase.13–15
As noted above, mutations in P5CS have been reported
with two types of clinical presentations. In the ﬁrst report,
patients exhibited developmental phenotypes similar to
cutis laxa type 2, together with hyperammonemia. More
recently, a different mutation in P5CS was reported in
a family with a neurocutaneous syndrome also closely
resembling cutis laxa type 2 but without any obvious
metabolic abnormalities. If these are loss-of-function
mutations, the result would presumably be a reduction in
proline biosynthesis, due to reduction in cellular P5Cpools.
Similarly, loss of PYCR1 activity in our patients would be
expected to reduce proline biosynthesis. We measured
urinary proline levels in our patients. Consistent with the
hypothesis, thoughnot deﬁnitive, nonehad anydetectable
proline in theurine,whichplaces themat the lowendof the
normal urinary proline range of 0–67 umol/mmol creati-
nine. Blood proline levels were measured for the two male
patients, D05-09864 and 11556 (see Figure 1), who had
(nonfasting) levels of 116 and 282 mM, respectively. This
placed them within the normal range of 70–440 mM. The
P5CS patients have a much more severe neurologic pheno-
type than our patients: their degree of microcephaly is
greater (smaller heads) and their retardation much more
severe (nonambulatory), whereas our patients have onlyThe Ammild mental retardation. This could be due to differential
functioning of the two genes, or to allele-speciﬁc effects.
Ultimately, additional caseswill be required for thedetermi-
nationof the full rangeof genotype-phenotype correlations
of mutations in these two genes. In addition, there are
several reports of cases sharing clinical features of moya-
moya disease (MYMY2 [MIM 607151])and microcephalic
osteodysplastic primordial dwarﬁsm type II (MOPD2
[MIM 210720]).25–27 MYMY2 is a neurological condition
of the cerebral vasculature,28 but MOPD2 shares some
clinical features with ARCL2 and the neurocutaneous
syndrome.29,30 MOPD2 is associated with mutations
in pericentrin 2 on chromosome 21 (MIM 605925).31
However, MYMY2maps near the telomeric region on chro-
mosome 17q25, and a causative gene is yet to be identi-
ﬁed.32,33 Conceivably, the rare patients sharing clinical
features of MYMY2 and MOPD2 could result from a chro-
mosomal rearrangement on 17q25, including PYCR1 plus
an MYMY2 gene.
It is not immediately clear how reduction in proline
biosynthesis could lead to many of the cutis laxa clinical
manifestations. Proline is a major component of collagen,
although the loose-skin phenotype appearsmore related to
elastin. It is also unclear whether the observed circulating
blood (normal) and urine (low) proline levels accurately
reﬂect intracellular pools in the relevant tissues. However,
proline plays another, essentially unrelated role in cellular
metabolism, as part of an oxidative cycle involving NADH
or NADPH. This cycle has been implicated in stress
response in yeast and plants.34–37 Moreover, PYCR1 was
originally identiﬁed as an induced proliferation gene called
PIG45,38,39 suggesting a possible role in cell growth regula-
tion. There is another gene, PYCR2, on chromosome 1,
which carries out the same reduction reaction as PYCR1,
though possibly with a different cofactor. The differential
roles of these two enzymes in organogenesis and cognitiveerican Journal of Human Genetics 85, 120–129, July 10, 2009 125
Figure 4. PYCR1 Mutations and In Vivo RNA Analysis
(A) Genomic DNA sequence of affected patient 11556 (family 2: V:1), showing homozygous missense variant G-to-A at the last nucle-
otide of exon 6 of PYCR1 (position 2766 of the reference sequence ﬁle generated for the gene by NCBI Mapviewer). Uppermost and
lowermost traces are virtual chromatograms generated by the software from the consensus genome sequence. Inner chromatogram
traces are forward and reverse sequences of patient PCR product. Central panels are forward and reverse mutation calls by Mutation
Surveyor.
(B) Electrophoresis gel showing products of RT-PCR of RNA from blood with the use of exonic primers spanning PYCR1 exon 6. Lanes
correspond, respectively, to RNA from an unrelated control, sample 1780 from affected homozygote no. 11807 (see Figure 1, family 1,
VI:4), sample 1781 from unaffected heterozygote sibling no. 11804 (family 1, VI:3), sample 1782 from unaffected heterozygote parent126 The American Journal of Human Genetics 85, 120–129, July 10, 2009
Figure 5. Protein Domain Structure of
PYCR1 Indicating Effects of Deleting
Exon 6 Plus Premature Truncation in
Exon 7
Note that this represents alternative tran-
script isoform 2. Isoform 1 retains the
sequences between exons 7 and 8, leading
to an alternative carboxy-terminus. Exclu-
sion of exon 6 would similarly lead to
a frameshift and premature protein trunca-
tion of isoform 1.development remain to be understood.40 Interestingly,
a genetic hyperprolinemia syndrome has been suggested
in schizophrenia, supporting a role of proline in normal
brain development.41 The genetic results suggest that
proline metabolism may be an attractive target for novel
therapeutics for skin conditions and, perhaps, wound heal-
ing.42,43 Common genetic variants in proline-pathway
genes could conceivably be involved in normal aging
processes.
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